Britain Courts Anthropic Amid US Defense Department Dispute 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
BUENA, N.J., July 28, 2017 -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Tuesday, August 8, 2017 to discuss the 2nd quarter 2017 financial results and business update.
The Company invites you to listen to the call by dialing 1-866-393-8366. International participants should call 1-409-350-3154. Participants should ask to be joined into the Teligent, Inc. call.
This call is being webcast and can be accessed in the Investor Relations Section of Teligent Inc.'s website at www.teligent.com.
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.
Contact: Jenniffer Collins Teligent, Inc. (856) 697-4379 www.teligent.com
